Osteoarthritis, Peripheral Neuropathy
Conditions
Keywords
pain
Brief summary
Patients having completed former trials T1001-01 or T1001-02 will undergo one blood sampling for genotyping purposes. In addition they will compete the personality questionnaires they had completed in the former trial.
Interventions
GENETICBlood sampling for genotyping
Venous punction of maximum 10 millilitres
OTHERPersonality Questionnaires completion
Completion of the following questionnaires: Multidimensional Personality Questionnaire (MPSQ), Interpersonal Reactivity Index (IRI) and Behavioral inhibition system/ Behavioral activation systems (BISBAS) questionnaires
Sponsors
Tools4Patient
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* have completed T1001-01 or T1001-02 study (Visit 5 completed) * are men or women of at least 18 years of age * have given written informed consent approved by the relevant Ethics Committee governing the study sites
Exclusion criteria
* have any close relationship with the Investigators or the Sponsor * are under legal protection, according to the national law
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with Single Nucleotide Polymorphisms (SNPs) variation of catechol-O-methyltransferase | Time zero equals baseline | SNPs will be analyzed with Sanger based genotyping or equivalent method |
| Number of participants with SNPs variation of monoamine oxidase | Time zero equals baseline | SNPs will be analyzed with Sanger based genotyping or equivalent method |
| Number of participants with SNPs variation of dopamine B hydroxylase | Time zero equals baseline | SNPs will be analyzed with Sanger based genotyping or equivalent method |
| Number of participants with SNPs variation of dopamine receptor 3 | Time zero equals baseline | SNPs will be analyzed with Sanger based genotyping or equivalent method |
| Number of participants with SNPs variation of brain-derived neurotropic factor genes | Time zero equals baseline | SNPs will be analyzed with Sanger based genotyping or equivalent method |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with SNPs variation of fatty acid amid hydrolase gene | Time zero equals baseline | SNPs will be analyzed with Sanger based genotyping or equivalent method |
| Number of participants with SNPs variation of tryptophan hydroxylase-2 | Time zero equals baseline | SNPs will be analyzed with Sanger based genotyping or equivalent method |
| Assessment of Cronbach alpha of the personality questionnaire used in this study and the former ones | Time zero equals baseline | Cronbach's alpha between 0 and 1 |
| Number of participants with SNPs variation of 5-hydroxytryptamine transporter | Time zero equals baseline | SNPs will be analyzed with Sanger based genotyping or equivalent method |
| Number of participants with SNPs variation of 5-hydroxytryptamine receptor 2A | Time zero equals baseline | SNPs will be analyzed with Sanger based genotyping or equivalent method |
| Number of participants with SNPs variation of serotonin transporter gene-linked polymorphic region genes | Time zero equals baseline | SNPs will be analyzed with Sanger based genotyping or equivalent method |
| Number of participants with SNPs variation of opioid receptor gene | Time zero equals baseline | SNPs will be analyzed with Sanger based genotyping or equivalent method |
Countries
Belgium, France
Outcome results
None listed